Welcome to our dedicated page for Volitionrx news (Ticker: VNRX), a resource for investors and traders seeking the latest updates and insights on Volitionrx stock.
VolitionRx Limited (NYSE American: VNRX) is a multi-national epigenetics company whose news flow centers on the development, validation, and commercialization of nucleosome-based blood tests for human and veterinary medicine. Company updates frequently highlight progress across its Nu.Q® platform, including cancer-focused assays, NETosis-related biomarkers, and companion animal diagnostics.
Readers of this VNRX news page can expect coverage of clinical study results, technology milestones, and collaborations. Recent announcements have described breakthrough clinical data for the Nu.Q® Vet Feline assay in detecting lymphoma in cats, positioning it as a potential simple, affordable blood-based liquid biopsy test for feline cancer. Other news has detailed the first commercial sale of Nu.Q® Cancer assays to a major European cancer center for internal certification ahead of routine clinical use in lung cancer management.
VolitionRx also issues news on its role in sepsis and NETosis research. The company has reported inclusion of its Nu.Q® NETs H3.1 assay as the sole biomarker in a French government-backed real-world program evaluating early detection of sepsis, and has highlighted broader work on NETs biomarkers and point-of-care nucleosome testing. Additional updates cover scientific advances such as its Capture-Seq™ method for enriching ultrashort transcription factor-bound DNA fragments in plasma, which the company positions as a potential foundation for accurate, lower-cost liquid biopsy tests.
Investors and followers will also find announcements on business reviews, licensing and co-marketing agreements with diagnostic companies, capital-raising transactions, and veterinary initiatives such as donations of Nu.Q® Vet Cancer Tests to crisis response dogs. This page aggregates these developments so that readers can track how VolitionRx’s clinical, commercial, and financial activities evolve over time.
Xenetic Biosciences (NASDAQ: XBIO) and VolitionRx Limited (NYSE AMERICAN: VNRX) announced a collaboration to develop Neutrophil Extracellular Traps (NETs) targeted, adoptive cell therapies for cancer treatment. The program aims to evaluate the integration of Volition's Nu.Q® NETs Test with Xenetic's DNase-Armored CAR T platform to potentially address multiple solid tumor types. Volition will fund the research, sharing proceeds from commercialization. The collaboration highlights both companies' commitment to innovative cancer therapies and reflects Xenetic's recent acquisition of the DNase platform.
VolitionRx Limited (NYSE AMERICAN: VNRX) has announced the pricing of its underwritten public offering of 3,000,000 shares at $2.00 per share, aiming to raise gross proceeds of approximately $6 million. An additional 450,000 shares may be purchased by the underwriter for overallotments. The offering is set to close around August 2, 2022. Proceeds will fund research, development, clinical studies, and working capital, including potential strategic acquisitions.
VolitionRx Limited (NYSE AMERICAN: VNRX) announced an underwritten public offering of its common stock, with all shares offered by the company. The offering includes a 30-day option for the underwriter to purchase an additional 15% of shares at the public offering price. The exact terms will depend on market conditions, and there is no guarantee of completion. Newbridge Securities Corporation is the sole book-running manager. The offering is made under a shelf registration statement previously filed with the SEC. A preliminary prospectus has been filed and is available on the SEC's website.
VolitionRx Limited (NYSE AMERICAN: VNRX) presented new data on its Nu.Q® NETs test at the ISTH Congress on July 13, 2022. The research, conducted with the University of Namur and QUALIblood, explores NETosis biomarkers in sepsis and COVID-19. Key findings include a correlation between Nu.Q® NET levels and the SOFA score, potentially aiding in patient diagnosis. Volition's Chief Scientific Officer emphasized the significance of this congress for building collaborations and advancing clinical applications of Nu.Q® tests in Europe.
VolitionRx Limited (VNRX) has announced the CE marking of its Nu.Q® NETs test for the detection and evaluation of NETosis, allowing clinical use in over 27 European countries. This test can detect NETosis through routine blood tests, offering significant commercial potential with a Total Addressable Market of approximately $6.5 billion for sepsis in Europe. The company expects to start commercialization in the first half of 2023. The test aims to support physicians in managing diseases associated with NETosis, including sepsis and COVID-19.
VolitionRx Limited (VNRX) reported financial results for Q1 2022, highlighting a net loss of $7.7 million compared to $6.1 million in Q1 2021. Cash reserves increased to $23.7 million, boosted by a $10 million milestone payment from Heska Corporation following a major licensing agreement for the Nu.Q® Vet Cancer Screening Test. The company is also expanding its operations with new hires and recent product launches in Singapore. Upcoming milestones include further licensing agreements, sales of test components, and clinical studies.
VolitionRx Limited (NYSE AMERICAN: VNRX) will hold a conference call on May 12, 2022, at 8:30 a.m. ET to discuss its Q1 2022 financial results and business updates. The call will feature CEO Cameron Reynolds and other executives. Additionally, a Capital Markets Day is scheduled for May 13, 2022, at 10:00 a.m. ET at the New York Stock Exchange. These events aim to provide insight into recent developments and future milestones within the company.
VolitionRx Limited (NYSE AMERICAN: VNRX) will host a hybrid Capital Markets Day on May 13, 2022, at 10 a.m. Eastern Time. The event, held at Siebert Hall, NYSE, will feature the executive team providing strategic updates and discussing key growth drivers. Topics include veterinary market opportunities, clinical results, and financial metrics. Attendees can register for virtual participation. Presentations will be available on the company’s website, with a replay offered post-event.
VolitionRx Limited (NYSE AMERICAN: VNRX) announced the launch of its Nu.Q® Vet Cancer Test in Asia via distributor SAGE Healthcare on April 25, 2022. Following their appointment in December 2021, SAGE has commenced marketing the test, which aims to facilitate early cancer detection in pets. CEO Dr. Jasmine Kway emphasized the growing pet ownership in Asia, presenting a significant market opportunity for the test. SAGE plans to expand the product's availability to other Asian markets.
VolitionRx Limited (NYSE AMERICAN: VNRX) has appointed Sharon Ballesteros as the U.S. Head of Quality and Development Process, effective April 4, 2022. Ballesteros brings over 20 years of experience from her previous roles at Siemens Health Diagnostics and GRAIL. This move supports Volition's expansion efforts in California, including a new 6,000 ft lab in Carlsbad. The company aims to enhance its regulatory processes to commercialize its Nu.Q® diagnostic products for various diseases. A warrant for 54,000 shares at $3.05 per share was granted to Ballesteros as part of her appointment.